NASDAQ · Biotechnology · USD

CG Oncology, Inc. (CGON) Stock Analysis

CG Oncology, Inc. (CGON) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CGON

$62.24

+$0.31 (+0.50%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGON with… →

CGON Key Statistics

As of Oct 21, 2026

Trading

Open: $62.43
Previous Close: $61.93
Day's Range: 61.93–63.57
52-Week Range: 35.80–80.97
Volume: 530.04K
Beta: 0.28

Valuation

Market Cap: $5.53B
P/E Ratio: unprofitable
P/S ratio: 888.11
EPS (ttm): −2.69

Financials (FY)

Revenue (FY): $4.04M+254.70%
Net Income (FY): −$161.00M
Shares Outstanding: 88.64M
1-Year Return: +44.54%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 876.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CGON closed at $62.24, +44.54% over 1 year.

CG Oncology, Inc. (CGON) has a market capitalization of $5.53B.

In fiscal 2025, CGON reported revenue of $4.04M.

CGON Stock Return by Calendar Year

CG Oncology, Inc. (CGON) return since Jan 2024: what $10,000 became

1 year: $10,000 $14,454; +44.54%
Since Jan 2024: $10,000 $16,745; +67.45%

If you had invested $10,000 in CG Oncology, Inc. (CGON) at the close on January 25, 2024, the earliest close on record here, it would have been worth $16,745 at the close on October 21, 2026: +67.45% in total, +20.72% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−22.84%+44.77%+49.90%

202420252026*

Year	Return
2026 (partial year)	+49.90%
2025	+44.77%
2024	−22.84%

As of October 21, 2026.

CGON Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$4.04M	−$161.00M	−3,985.0%
2024	$1.14M	−$88.04M	−7,729.5%
2023	$204.00K	−$48.61M	−23,827.0%
2022	$191.00K	−$35.44M	−18,556.5%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$4.04M	−$607.00K	−$190.77M	−$161.00M	−3,985.0%
2024	$1.14M	$1.14M	−$114.67M	−$88.04M	−7,729.5%
2023	$204.00K	$204.00K	−$55.45M	−$48.61M	−23,827.0%
2022	$191.00K	—	−$35.25M	−$35.44M	−18,556.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CGON Valuation vs Biotechnology Median

Median of 608 stocks

Metric	CGON	Biotechnology median	vs median
P/S ratio	888.11	13.30	66.8x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values CG Oncology, Inc. (CGON) at $5.53B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 142.

Over the past 52 weeks the price has ranged from $35.80 to $80.97. CGON last closed at $62.24 on October 21, 2026. That is +$0.31 (+0.50%) against the previous close. The latest close sits 73.85% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.04M. Against the prior fiscal year total of $1.14M, that is a change of +254.70%. The same year closed with a net loss of $161.00M. Trailing earnings per share are −2.69.

Across the 4 fiscal years on file, revenue moves from $191.00K in 2022 to $4.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 888.11 times revenue. On price-to-sales that is 66.8 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +44.54%. The stored price history starts on January 25, 2024, and the total return since then is +67.45%. Beta against the wider market is reported at 0.28. Annualized volatility over the trailing 2 years is 61.18%.

Growth & Income

The record shows no dividend for CGON.

The strongest complete calendar year on file is 2025 at +44.77%; the weakest is 2024 at −22.84%. 2026 is still running; the total return is +49.90% year to date.

Peer Comparison

CG Oncology, Inc. (CGON) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
CG Oncology, Inc.	CGON	$5.53B	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. CG Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About CG Oncology, Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Visit website →